Interferon-β in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10?

Current Opinion in Neurology

Volumn 14, Issue 3, 2001, Pages 361-368

  Karp, Christopher L ^a,d   Van Boxel Dezaire, Anette H H ^b   Byrnes, Adriana A ^c   Nagelkerken, Lex ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b TNO   (Netherlands)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12;

ANTIVIRAL ACTIVITY; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW;

ANIMALS; CLINICAL TRIALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-12; MULTIPLE SCLEROSIS;

EID: 0034982136     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200106000-00016     Document Type: Review

References (75)

1. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
2. Identification of auto-antibodies associated with myelin damage in multiple sclerosis
3. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement
4. Axonal pathology in multiple sclerosis: Relationship to neurologic disability
5. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system
6. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
7. Multiple sclerosis
8. Immunomodulatory effects of interferon beta-1a in multiple sclerosis
9. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment
10. Type I interferons keep activated T cells alive
11. Interferon-beta mediates stromal cell rescue of T cells from apoptosis
12. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis
13. Interferon alpha augments activation induced T celt death by upregulation of Fas (CD95/APO-1) and Fas ligand expression
14. No induction of apoptosis by IFN-beta in human antigen-specific T cells
15. + T cells
16. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients
17. Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients
18. VLA-4/CD49d down-regulated on primed T lymphocytes during interferon- beta therapy in multiple sclerosis
19. Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN- beta
20. Induction of IL-1 receptor antagonist by interferon beta: Implication for the treatment of multiple sclerosis
21. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-larpha by interferon-beta
22. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b
23. Interleukin-12: A cytokine at the interface of inflammation and immunity
24. Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection
25. Astrocytes and microglia produce interleukin-12 p40
26. Toll-like receptors in the induction of the innate immune response
27. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
28. Receptor mediated subversion of macrophage cytokine production by intracellular pathogens
29. Interleukin-12 primes human CD4 and CD8 T cell crones for high production of both interferon-gamma and interleukin-10
30. Interleukin-10
31. Uncoupling of inflammatory chemokine receptors by IL-10: Generation of functional decoys
32. IL-10 and the dangers of immune polarization: Excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis
33. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
34. Interferon-β in multiple sclerosis: Is IL-12 suppression the key?
35. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus)
36. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)
37. An interleukin (IL)-10/IL-12 immune-regulatory circuit controls susceptibility to autoimmune disease
38. Interleukin-12: Amiss in MS
39. IL-10 fails to abrogate experimental autoimmune encephalomyelitis
40. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis
41. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis
42. Exacerbations of multiple sclerosis in patients treated with gamma interferon
43. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions
44. Interleukin-12 and perforin mrna expression is augmented in blood mononuclear cells in multiple sclerosis
45. Decreased IL-10 and increased IL-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
46. +? T cells va CD40 ligand
47. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
48. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
49. Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation
50. Cytokine production and surface marker expression in acute and stable multiple sclerosis: Altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis
51. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis
52. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
53. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis
54. + T cell IL-10 production in stable relapsing multiple sclerosis
55. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS
56. Augmented type 1 cytokines and human endogenous retroviruses specific immune responses in patients with acute multiple sclerosis
57. The adhesion molecule and cytokine profile of multiple sclerosis lesions
58. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection
59. In vive microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas
60. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
61. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear ceils in an IL-10-dependent mechanism: Relevance to IFN-beta-1b therapeutic effects in multiple sclerosis
62. + T cells and monocytes
63. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors
64. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs
65. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells
66. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
67. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2
68. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis
69. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms
70. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis
71. IFN-beta modulates specific T cell responses in vitro but does not affect experimental autoimmune encephalomyelitis in the SJL mouse
72. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
73. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
74. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4
75. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-beta therapy